<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845945</url>
  </required_header>
  <id_info>
    <org_study_id>2021-12637</org_study_id>
    <nct_id>NCT04845945</nct_id>
  </id_info>
  <brief_title>MISP 60528 Pneumococcal Vaccination</brief_title>
  <official_title>Response to Guideline-concordant Pneumococcal Vaccination Strategy in Cardiac Transplant Candidates and Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to use two different blood tests (ELISA and OPA) to study response to&#xD;
      pneumococcal vaccination administered as per standard guidelines in patients who are&#xD;
      undergoing workup for heart transplant (whether or not they have undergone LVAD implantation&#xD;
      or have undergone heart transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will be receiving vaccination consistent with standard of care guidelines,&#xD;
      regardless of study participation. The additional risk of study participation would be the&#xD;
      risks associated with venipuncture (injury to vessel or nerve, syncope).&#xD;
&#xD;
      Patients will not accrue benefits personally. However, participation will help others by&#xD;
      identifying whether current vaccination strategies in this population are adequate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">February 14, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Antibody levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype ELISA response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Antibody production to specific serotype</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">45</enrollment>
  <condition>Heart Transplant Infection Prevention</condition>
  <arm_group>
    <arm_group_label>PCV13 only</arm_group_label>
    <description>Draw blood for ELISA and OPA, then administer PCV13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPS23 only</arm_group_label>
    <description>Draw blood for ELISA and OPA, then administer PPS23</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCV13 and PPS23</arm_group_label>
    <description>Draw blood for Administer PPS23 then draw blood again ELISA and OPA, then administer PCV13</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV13</intervention_name>
    <description>Blood draw after the vaccination</description>
    <arm_group_label>PCV13 and PPS23</arm_group_label>
    <arm_group_label>PCV13 only</arm_group_label>
    <other_name>PPS23</other_name>
    <other_name>PCV13 and PPS23</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We are excluding infants and children as they are immunologically different from adults,&#xD;
        respond to vaccinations differently, and guidelines for childhood vaccination are different&#xD;
        from those for adult vaccination.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or over&#xD;
&#xD;
          -  Either undergoing evaluation for heart transplant (with or without LVAD receipt), or&#xD;
             having received a heart transplant&#xD;
&#xD;
          -  Receiving a dose of PCV13 or PPSV23 (or both sequentially) concordant with AST&#xD;
             guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infants and children under age 18&#xD;
&#xD;
          -  Subjects without the capacity to consent&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Already up to date on pneumococcal vaccination or declining vaccination&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Vagish Hemmige, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center, Infectious Diseases</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

